110 related articles for article (PubMed ID: 29723517)
1. Inhibitory effect of α-terpinyl acetate on cytochrome P450 2B6 enzymatic activity.
Lee Y; Park HG; Kim V; Cho MA; Kim H; Ho TH; Cho KS; Lee IS; Kim D
Chem Biol Interact; 2018 Jun; 289():90-97. PubMed ID: 29723517
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
Lau AJ; Chang TK
Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
[TBL] [Abstract][Full Text] [Related]
3. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6.
Bhateria M; Ramakrishna R; Puttrevu SK; Saxena AK; Bhatta RS
Chem Biol Interact; 2016 Aug; 256():257-65. PubMed ID: 27387538
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibitory effects of machilin A isolated from Machilus thunbergii on human cytochrome P450 1A and 2B6.
Kim SJ; You J; Choi HG; Kim JA; Jee JG; Lee S
Phytomedicine; 2015 Jun; 22(6):615-20. PubMed ID: 26055126
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.
Nirogi R; Palacharla RC; Mohammed AR; Manoharan A; Ponnamaneni RK; Bhyrapuneni G
Chem Biol Interact; 2015 Mar; 230():9-20. PubMed ID: 25656918
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants.
Wang PF; Neiner A; Kharasch ED
Drug Metab Dispos; 2020 Jun; 48(6):438-445. PubMed ID: 32238417
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) by human liver microsomes: identification of cytochrome P450 2B6 as the major enzyme involved.
Erratico CA; Szeitz A; Bandiera SM
Chem Res Toxicol; 2013 May; 26(5):721-31. PubMed ID: 23537005
[TBL] [Abstract][Full Text] [Related]
8. Psoralen, a mechanism-based inactivator of CYP2B6.
Ji L; Lu D; Cao J; Zheng L; Peng Y; Zheng J
Chem Biol Interact; 2015 Oct; 240():346-52. PubMed ID: 26335194
[TBL] [Abstract][Full Text] [Related]
9. Deoxyshikonin reversibly inhibits cytochrome P450 2B6.
Kim JH; Choi SM; Shreatha R; Jeong GS; Jeong TC; Lee S
Biopharm Drug Dispos; 2020 Apr; 41(4-5):221-225. PubMed ID: 32364297
[TBL] [Abstract][Full Text] [Related]
10. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Lv J; Hu L; Zhuo W; Zhang C; Zhou H; Fan L
Pharmacogenet Genomics; 2016 Feb; 26(2):80-7. PubMed ID: 26580670
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of all-trans, 9-cis, and 13-cis isomers of retinal by purified isozymes of microsomal cytochrome P450 and mechanism-based inhibition of retinoid oxidation by citral.
Raner GM; Vaz AD; Coon MJ
Mol Pharmacol; 1996 Mar; 49(3):515-22. PubMed ID: 8643091
[TBL] [Abstract][Full Text] [Related]
12. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6.
Dicke KE; Skrlin SM; Murphy SE
Drug Metab Dispos; 2005 Dec; 33(12):1760-4. PubMed ID: 16174803
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
14. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine.
Jushchyshyn MI; Wahlstrom JL; Hollenberg PF; Wienkers LC
Drug Metab Dispos; 2006 Sep; 34(9):1523-9. PubMed ID: 16782764
[TBL] [Abstract][Full Text] [Related]
16. The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.
Gao LC; Liu FQ; Yang L; Cheng L; Dai HY; Tao R; Cao SP; Wang D; Tang J
Eur J Clin Pharmacol; 2016 Oct; 72(10):1205-1213. PubMed ID: 27439448
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.
Desta Z; Metzger IF; Thong N; Lu JB; Callaghan JT; Skaar TC; Flockhart DA; Galinsky RE
Antimicrob Agents Chemother; 2016 Nov; 60(11):6813-6822. PubMed ID: 27600044
[TBL] [Abstract][Full Text] [Related]
18. Measurement of in vitro cytochrome P450 2B6 activity.
Walsky RL; Obach RS
Curr Protoc Toxicol; 2009; Chapter 4():Unit4.27. PubMed ID: 23045012
[TBL] [Abstract][Full Text] [Related]
19. α-Terpinyl Acetate: Occurrence in Essential Oils Bearing
Vaičiulytė V; Ložienė K; Švedienė J; Raudonienė V; Paškevičius A
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670506
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cytochrome P450 2B6 by Astragalus extract mixture HT042.
Kim H; Lee Y; Kim V; Lee R; Bae SK; Kwak MK; Lee SH; Kim D
Toxicol Res; 2020 Jul; 36(3):195-201. PubMed ID: 32685423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
